Hims & Hers Health ( HIMS ) shares tumble after the US Food and Drug Administration (FDA) announced that the shortage in Eli Lilly's ( LLY ) weight loss drug, Zepbound, has been resolved. The stock falls in anticipation of lower demand as the supply of GLP-1 weight-loss drugs improves.

Julie Hyman and Josh Lipton examine the stock move and what investors need to know about the evolving GLP-1 market.

To watch more expert insights and analysis on the latest market action, check out more Market Domination here .

This post was written by Naomi Buchanan.